Howard Weiner was interviewed on NewsNation about Tiziana's nasal foralumab for the treatment of #AlzheimersDisease. Full Interview here: youtu.be/DIkhfrqDEbU?si… $TLSA

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy. Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease. $TLSA #Foralumab #MSA #FDA #Phase2 #ClinicalTrial

$TLSA Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA tinyurl.com/28xsr7u3 @tizianals #TLSA

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy. There are no FDA-approved treatments that alter its course, creating a critical need for new therapeutic strategies. $TLSA #MSA #ClinicalTrial tizianalifesciences.com/tiziana-life-s…

Tiziana Life Sciences highlighted as #1 "Top 5 Small-cap Biotech Stocks of 2025" $TLSA nasdaq.com/articles/top-5…

Foralumab for Multiple Sclerosis youtu.be/1KlKHHE9_aY?si…

Today we announced that our Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital. tizianalifesciences.com/tiziana-life-s…

U.S. Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury. This funding builds on our platform beyond autoimmune and neuroinflammatory diseases into large, underserved neurological indications. $TLSA

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress. $TLSA #ECTRIMS2025 #MultipleSclerosis #MS #SPMS tizianalifesciences.com/tiziana-life-s…

Tiziana to Advance Its Second Asset TZLS-501 - A Fully Human IL-6R Monoclonal Antibody. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ ( $NVS ) recent acquisition of Tourmaline Bio ( $TRML ) for approximately $1.4 billion. Tiziana

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia. $TLSA #LSIF2025 #JPMorgan KAIMRC كيمارك tizianalifesciences.com/tiziana-life-s…

Tiziana are looking forward to the keynote speech by Dr. Saef Izzy of BWH. Dr. Izzy's work with Tiziana's intranasal anti-CD3 in Spinal Cord Injury and Traumatic Brain Injury have shown some promising results, and this has been recognized by the U.S. DoD and also Stepping Strong Center

A great start to the conference in Riyadh, Saudi Arabia, with Saef Izzy presenting the keynote speech at The Life Sciences Innovation Forum 2025 KAIMRC كيمارك $TLSA #LSIF2025

Just Announced: The 2025 Nobel Prize in Physiology or Medicine honored the discovery of FOXP3⁺ regulatory T cells (Tregs) as key mediators of immune tolerance. This breakthrough laid the foundation for therapies that restore immune balance by enhancing Treg activity. Foralumab,

Tiziana Life Sciences $TLSA has been notified that Laura Natalia Monica Fonda now beneficially owns 6,805,556 shares of Tiziana, representing 5.7% of the company. Link to SEC filing: sec.gov/Archives/edgar…

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy. Tiziana’s management team, led by CEO Ivor Elrifi, will also engage in one-on-one partnering meetings with leading biopharma executives and investors. $TLSA EBD Group

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference. The Jefferies Healthcare Conference is one of Europe’s premier investor forums, attracting leading global healthcare companies, institutional investors, and industry thought leaders. #JefferiesHealthcare

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program. $TLSA MGH Neurology #ALSresearch #ALS tizianalifesciences.com/tiziana-life-s…

The Sean M. Healey & AMG Center for ALS at Mass General Brigham has selected Tiziana Life Sciences as one of the companies to enter the Healey ALS MyMatch Program for testing intranasal foralumab in a biomarker-driven phase 2a clinical trial for ALS. This trial is partially

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company. Tiziana shareholders at the record date will retain value from TZLS-501 through the distribution in specie of shares in the new TZLS-501 listed entity. $TLSA tizianalifesciences.com/tiziana-life-s…